Changes in bone biomarkers in antiretroviral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/R) or zidovudine/lamivudine/lopinavir/ritonavir (AZT/3TC/LPV/R) help explain limited loss of bone mineral density over first 12 months

✍ Scribed by B.F. Murray⁎; M.G. van Vonderen; P.W. Mallon; P. Doran; M.A. van Agtmael; S.A. Danner; P. Lips; P. Reiss

• Book ID: 116325629
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 77 KB
• Volume: 50
• Category: Article
• ISSN: 8756-3282
• DOI: 10.1016/j.bone.2012.02.525